Rindopepimut

Identification

Name
Rindopepimut
Accession Number
DB05374  (DB05612)
Type
Small Molecule
Groups
Investigational
Description

Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH). The US FDA granted it Breakthrough Therapy Designation for glioblastoma in Feb 2015.

Synonyms
  • Rintega
External IDs
ALT-110 / PF-04948568
Categories
UNII
K3L4X0501F
CAS number
1108208-65-6
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for use/treatment in brain cancer.

Pharmacodynamics
Not Available
Mechanism of action

CDX-110 is an investigational immunotherapy that targets the tumor specific molecule EGFRvIII, a functional variant of the epidermal growth factor receptor (EGFR), which is a protein that has been well validated as a target for cancer therapy. This particular variant, EGFRvIII occurs in about 40 percent of Glioblastoma Multiforme (GBM) patients. It was discovered in a collaborative effort between Dr. Bert Vogelstein and Dr Albert Wong at Johns Hopkins University and Dr. Darell Bigner at Duke University. Unlike EGFR, EGFRvIII is not present in normal tissues, suggesting this target will enable the development of a tumor-specific therapy for cancer patients. Furthermore, EGFRvIII is a transforming oncogene that can directly contribute to cancer cell growth. While originally discovered in GBM, the most common and aggressive form of brain cancer, the expression of EGFRvIII has also been observed in various other cancers such as breast, ovarian, metastatic prostate, colorectal, and head & neck cancers. Celldex has exclusive rights to EGFRvIII vaccines and is pursuing the development of CDX-110 for GBM therapy, as well as in other cancers through additional clinical studies.

TargetActionsOrganism
UEpidermal growth factor receptorNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Rindopepimut.
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rindopepimut.
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Rindopepimut.
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Rindopepimut.
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Rindopepimut.
AbetimusThe risk or severity of adverse effects can be increased when Abetimus is combined with Rindopepimut.
AbituzumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Abituzumab.
ActeosideThe risk or severity of adverse effects can be increased when Acteoside is combined with Rindopepimut.
AdalimumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Adalimumab.
AdecatumumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Adecatumumab.
Food Interactions
Not Available

References

General References
  1. Zussman BM, Engh JA: Outcomes of the ACT III Study: Rindopepimut (CDX-110) Therapy for Glioblastoma. Neurosurgery. 2015 Jun;76(6):N17. doi: 10.1227/01.neu.0000465855.63458.0c. [PubMed:25985004]
External Links
PubChem Substance
347910109
Wikipedia
Rindopepimut

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1TerminatedTreatmentBrain Cancer / Brain Stem Tumors / Pontine Tumors1
Not AvailableNo Longer AvailableNot AvailableRecurrent GBM1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ubiquitin protein ligase binding
Specific Function
Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TG...
Gene Name
EGFR
Uniprot ID
P00533
Uniprot Name
Epidermal growth factor receptor
Molecular Weight
134276.185 Da

Drug created on November 18, 2007 11:24 / Updated on August 02, 2018 05:30